摘要
过氧化物酶体增殖物激活受体γ是一类主要调控糖脂代谢与脂肪细胞分化的核受体,与肥胖、胰岛素抵抗和糖尿病的发生发展密切相关,其激动剂作为胰岛素增敏剂治疗2型糖尿病也被临床广泛应用。近年来,随着对PPARγ信号通路和胰岛素增敏剂的深入研究,使我们对选择性PPARγ调节剂类胰岛素增敏剂的认识不断完善和更新。该文主要阐述选择性PPARγ调节剂类胰岛素增敏剂的作用机制和药物研究的最新进展。
PPARγ is a kind of nuclear receptors responsible for the regulation of glucose and lipid metabolisim and adipocyte difference, which is related with the pathogenesis of obesity, insulin resistance and type 2 diabetes mellitus. PPARγagonists as insulin sensitizer have been used in the clinical treatment for type 2 diabetes for more than decades. Recently, with the further research plunging into the PPAR signaling pathway and insulin sensitizer, the recognition of this crucial nuclear receptor has been renewed and developed. The aim of this review is to report the update research outcomes.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2008年第2期149-152,共4页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No30371672)
北京市自然科学基金资助项目(No7042042)